Globeflex Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Globeflex Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,000	Closed	-$156K	–	497
2020 Q4	$156K	Hold	1,000	–	–	0.03%	390
2020 Q3	$114K	Sell	1,000 -1,200	-55%	-$129K	0.03%	396
2020 Q2	$247K	Hold	2,200	–	–	0.06%	378
2020 Q1	$198K	Hold	2,200	–	–	0.06%	362
2019 Q4	$238K	Hold	2,200	–	–	0.04%	405
2019 Q3	$215K	Hold	2,200	–	–	0.05%	385
2019 Q2	$288K	Hold	2,200	–	–	0.06%	360
2019 Q1	$297K	Sell	2,200 -700	-24%	-$87K	0.06%	351
2018 Q4	$282K	Hold	2,900	–	–	0.07%	347
2018 Q3	$403K	Buy	+2,900	New	+$364K	0.08%	339
2015 Q1	–	Sell	-6,020	Closed	-$1.11M	–	622
2014 Q4	$1.11M	Sell	6,020 -23,720	-80%	-$4.4M	0.22%	191
2014 Q3	$4.93M	Sell	29,740 -8	-0%	-$1.31K	0.56%	79
2014 Q2	$4.65M	Buy	29,748 +102	+0.3%	+$16.1K	0.51%	81
2014 Q1	$4.51M	Buy	+29,646	New	+$4.71M	0.52%	81

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Globeflex Capital's ALXN Position: Q1 2021 in Review

Globeflex Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,000 shares — an estimated $156K sold.

Globeflex Capital first reported a position in ALXN in Q1 2014 and held it in 14 quarters. The position peaked at $4.93M in Q3 2014. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Globeflex Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Globeflex Capital sold 1,000 Alexion Pharmaceuticals shares in Q1 2021, an estimated $156K.
Globeflex Capital first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 14 quarters.
Globeflex Capital's Alexion Pharmaceuticals position peaked at $4.93M in Q3 2014.
754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Globeflex Capital's 13F filing for Q1 2021, filed 14 May 2021.